|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- Clinical: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Jul 25, 2014
P=N/A, N=28, Not yet recruiting, Sponsor: Johns Hopkins University
- | Enrollment change: A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis (clinicaltrials.gov) - Jul 17, 2014
P1/2, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
N=60 --> 24
- Ossirene (AS101) / Cassiopea, Feramda
Enrollment change: Topical Application of AS101 for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Jul 17, 2014
P2, N=5, Terminated, Sponsor: BioMAS Ltd
N=60 --> 24 N=20 --> 5
- || BMS-981164 / BMS
Enrollment change, Trial primary completion date: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Jul 14, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
N=20 --> 5 N=128 --> 88 | Trial primary completion date: Nov 2015 --> Jan 2015
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=128 --> 88 | Trial primary completion date: Nov 2015 --> Jan 2015 Trial primary completion date: Jun 2014 --> Dec 2014
- |||||| Ilaris (canakinumab) / Novartis
Enrollment open: CLUSTER: Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (clinicaltrials.gov) - Jul 12, 2014
P3, N=180, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- | Ilaris (canakinumab) / Novartis
Trial completion: Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). (clinicaltrials.gov) - Jul 12, 2014
P2, N=21, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Alesion (epinastine) / Boehringer Ingelheim
New P3 trial: WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients (clinicaltrials.gov) - Jul 8, 2014
P3, N=62, Completed, Sponsor: Boehringer Ingelheim
- |||||||||| Alesion (epinastine) / Boehringer Ingelheim
New P3 trial: WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients (clinicaltrials.gov) - Jul 8, 2014
P3, N=162, Completed, Sponsor: Boehringer Ingelheim
- New P3 trial: Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients (clinicaltrials.gov) - Jul 1, 2014
P3, N=30, Not yet recruiting, Sponsor: Mahidol University
- Pandel (hydrocortisone probutate) / Novartis
Trial primary completion date: Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population (clinicaltrials.gov) - Jun 27, 2014
P4, N=19, Suspended, Sponsor: Fougera Pharmaceuticals Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2011 --> Dec 2014
- New P3 trial: Study to Determine the Pharmacokinetics of Product 0405 (clinicaltrials.gov) - Jun 27, 2014
P3, N=0, Withdrawn, Sponsor: Fougera Pharmaceuticals Inc.
- New P3 trial: Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects (clinicaltrials.gov) - Jun 27, 2014
P3, N=0, Withdrawn, Sponsor: Fougera Pharmaceuticals Inc.
- New P3 trial: Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects (clinicaltrials.gov) - Jun 27, 2014
P3, N=0, Withdrawn, Sponsor: Fougera Pharmaceuticals Inc.
- Kineret (anakinra) / SOBI
Trial suspension: Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=70, Suspended, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Trial primary completion date: Dec 2011 --> Dec 2014 Recruiting --> Suspended
- Kineret (anakinra) / SOBI
Enrollment change, Trial suspension: Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=70, Suspended, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting --> Suspended N=900 --> 70 | Recruiting --> Suspended
- || tacrolimus topical / Generic mfg.
Trial primary completion date: Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis (clinicaltrials.gov) - Jun 19, 2014
P4, N=125, Completed, Sponsor: Astellas Pharma China, Inc.
N=900 --> 70 | Recruiting --> Suspended Trial primary completion date: Aug 2013 --> Nov 2013
- |||| tacrolimus topical / Generic mfg.
Trial completion, Trial primary completion date: Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis (clinicaltrials.gov) - Jun 19, 2014
P4, N=125, Completed, Sponsor: Astellas Pharma China, Inc.
Trial primary completion date: Aug 2013 --> Nov 2013 Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Nov 2013
- Biomarker: Biomarkers in Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- || Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Jun 18, 2014
P2, N=70, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Nov 2013 Trial primary completion date: May 2014 --> Sep 2014
- Enrollment change: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=35, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: May 2014 --> Sep 2014 N=55 --> 35
- Enrollment closed, Enrollment change: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=35, Active, not recruiting, Sponsor: Bayer
N=55 --> 35 Recruiting --> Active, not recruiting | N=55 --> 35
- || BMS-981164 / BMS
Trial primary completion date: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Jun 13, 2014
P1, N=128, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=55 --> 35 Trial primary completion date: May 2014 --> Nov 2015
- || BMS-981164 / BMS
Enrollment change: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Jun 10, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2014 --> Nov 2015 N=128 --> 88
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - Jun 4, 2014
P2, N=120, Recruiting, Sponsor: Bayer
N=128 --> 88 Not yet recruiting --> Recruiting
- | Ilaris (canakinumab) / Novartis
Trial primary completion date: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Jun 2, 2014
P3, N=15, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Sep 2015
- Toctino (alitretinoin) / Basilea
Trial primary completion date: Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. (clinicaltrials.gov) - Jun 1, 2014
P4, N=15, Terminated, Sponsor: Technische Universität Dresden
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Dec 2012 --> Mar 2012
- Toctino (alitretinoin) / Basilea
Trial termination: Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. (clinicaltrials.gov) - Jun 1, 2014
P4, N=15, Terminated, Sponsor: Technische Universität Dresden
Trial primary completion date: Dec 2012 --> Mar 2012 Not yet recruiting --> Terminated; delayed start of the trial, both treatment options already have market authorizations, study medication expired
- Toctino (alitretinoin) / Basilea
Enrollment change: Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. (clinicaltrials.gov) - Jun 1, 2014
P4, N=15, Terminated, Sponsor: Technische Universität Dresden
Not yet recruiting --> Terminated; delayed start of the trial, both treatment options already have market authorizations, study medication expired N=78 --> 15
- | New P1/2 trial: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - May 29, 2014
P1/2, N=15, Recruiting, Sponsor: TransDerm, Inc.
- || Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - May 29, 2014
P=N/A, N=90, Recruiting, Sponsor: University of Aarhus
N=78 --> 15 Trial primary completion date: Dec 2013 --> Jul 2014
- triamcinolone acetonide topical / Generic mfg.
Trial primary completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - May 26, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Dec 2013 --> Jul 2014 Trial primary completion date: Jun 2014 --> Jun 2015
- triamcinolone acetonide topical / Generic mfg.
Trial completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - May 26, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Jun 2014 --> Jun 2015 Trial completion date: Jun 2014 --> Jun 2015
- triamcinolone acetonide topical / Generic mfg.
Enrollment closed, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - May 26, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Trial completion date: Jun 2014 --> Jun 2015 Recruiting --> Active, not recruiting
- ||| AIMab7195 / Nestle
New P1 trial: Safety and Tolerability of XmAb (clinicaltrials.gov) - May 26, 2014
P1, N=64, Recruiting, Sponsor: Xencor, Inc.
- | Ilaris (canakinumab) / Novartis
Enrollment closed: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - May 19, 2014
P3, N=17, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Zoryve (roflumilast cream) / Arcutis
Trial primary completion date: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - May 18, 2014
P2, N=40, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2013 --> Mar 2014
- Zoryve (roflumilast cream) / Arcutis
Trial completion date: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - May 18, 2014
P2, N=40, Completed, Sponsor: Takeda
Trial primary completion date: Jul 2013 --> Mar 2014 Trial completion date: Jul 2013 --> Mar 2014
- | Zoryve (roflumilast cream) / Arcutis
Trial completion: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - May 18, 2014
P2, N=40, Completed, Sponsor: Takeda
Trial completion date: Jul 2013 --> Mar 2014 Recruiting --> Completed
- Trial initiation date: Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis (clinicaltrials.gov) - May 15, 2014
P=N/A, N=126, Not yet recruiting, Sponsor: Nestlé
Recruiting --> Completed Initiation date: Apr 2014 --> Jun 2014
- Trial primary completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Initiation date: Apr 2014 --> Jun 2014 Trial primary completion date: Jan 2015 --> May 2014
- Trial completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial primary completion date: Jan 2015 --> May 2014 Trial completion date: Jan 2015 --> May 2014
- Trial completion: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial completion date: Jan 2015 --> May 2014 Recruiting --> Completed
- || MK-8226 / Merck (MSD)
Trial primary completion date: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) - May 14, 2014
P1, N=170, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Sep 2014
- | MK-8226 / Merck (MSD)
Trial completion date: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) - May 14, 2014
P1, N=170, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2015 --> Sep 2014 Trial completion date: Jun 2015 --> Sep 2014
- || MK-8226 / Merck (MSD)
Enrollment closed: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) - May 14, 2014
P1, N=170, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2015 --> Sep 2014 Recruiting --> Active, not recruiting
- || Trial primary completion date: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - May 13, 2014
P=N/A, N=55, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jul 2014
- | Trial completion date: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - May 13, 2014
P=N/A, N=55, Recruiting, Sponsor: Bayer
Trial primary completion date: Jun 2014 --> Jul 2014 Trial completion date: Jun 2014 --> Jul 2014
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 13, 2014
P2, N=120, Not yet recruiting, Sponsor: Bayer
- cyclosporin A microemulsion / Generic mfg.
Trial primary completion date: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - May 5, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Rockefeller University
Trial completion date: Jun 2014 --> Jul 2014 Trial primary completion date: Mar 2013 --> Dec 2014